Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatology

Volumn 66, Issue 8, 2014, Pages 2091-2102

  Dougados, Maxime ^a   Van Der Heijde, Désirée ^b   Sieper, Joachim ^c   Braun, Jürgen ^d   Maksymowych, Walter P ^e   Citera, Gustavo ^f   Miceli Richard, Corinne ^g   Wei, James Cheng Chung ^h   Pedersen, Ron ⁱ   Bonin, Randi ⁱ   Rahman, Mahboob U ^i,j   Logeart, Isabelle ⁱ   Wajdula, Joseph ⁱ   Koenig, Andrew S ⁱ   Vlahos, Bonnie ⁱ   Alvarez, Daniel ⁱ   Bukowski, Jack F ⁱ  

^a SORBONNE UNIVERSITÉ   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RHEUMAZENTRUM RUHRGEBIET   (Germany)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Instituto de Rehabilitación Psicofísica and Argentine Rheumatologic Foundation Dr Osvaldo García Morteo   (Argentina)

^g BICÊTRE HOSPITAL   (France)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SPONDYLARTHRITIS;

EID: 84904957534     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38721     Document Type: Article

References (43)

1. Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
2. Heuft-Dorenbosch L, Landewe R, Weijers R, Wanders A, Houben H, van der Linden S, et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006; 65: 804-8.
3. Oostveen J, Prevo R, den Boer J, van de Laar M,. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study. J Rheumatol 1999; 26: 1953-8.
4. Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008; 58: 3413-8.
5. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J,. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37: 1039-45.
6. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
7. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2: ii1-44.
8. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
9. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-52.
10. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
11. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
12. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340-5.
13. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54: 678-81.
14. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
15. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58: 1981-91.
16. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis [published erratum appears in Arthritis Rheum 2010;62:3005]. Arthritis Rheum 2009; 60: 946-54.
17. Song IH, Hermann KG, Haibel H, Althoff CE, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70: 590-6.
18. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-22.
19. Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013; 72: 823-5.
20. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
21. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
22. Dougados M, Paternotte S, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011; 70: 249-51.
23. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, et al. Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis. Arthritis Care Res (Hoboken) 2012; 64: 290-4.
24. Dougados M, Braun J, Burgos-Vargas R, Gossec L, Maksymowych W, Sieper J, et al. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis [letter]. Ann Rheum Dis 2012; 71: 1103-4.
25. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of ankylosing spondylitis. London; June 23, 2005. URL: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003425.pdf.
26. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
27. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of ankylosing spondylitis. London; April 23, 2009. URL: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003424.pdf.
28. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70: 47-53.
29. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M,. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.
30. Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al, for the Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1811-8.
31. Van der Heijde D, Landewe R, Feldtkeller E,. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008; 67: 489-93.
32. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32.
33. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005; 53: 502-9.
34. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005; 53: 703-9.
35. Maksymowych WP, Lambert RG, Brown LS, Pangan AL,. Defining the minimally important change for the SpondyloArthritis Research Consortium of Canada spine and sacroiliac joint magnetic resonance imaging indices for ankylosing spondylitis. J Rheumatol 2012; 39: 1666-74.
36. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63: 1543-51.
37. Molto A, Paternotte S, Claudepierre P, Breban M, Dougados M,. Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort. Arthritis Rheumatol 2014; 66: 1734-44.
38. US Food and Drug Administration. Arthritis Drugs Advisory Committee. July 23, 2013 meeting of the Arthritis Drugs Advisory Committee. Silver Spring (MD): US Department of Health and Human Services; 2013.
39. Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 2011; 70: 799-804.
40. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-31.
41. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G,. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011; 70: 1292-5.
42. Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012; 71: 989-92.
43. Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, et al, on behalf of the Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65: 3096-106.